Mayo Clinic Cancer Center (MCCC) Senior Leadership encompasses the Director, Deputy Director Clinical Affairs, Deputy Director MCCC Arizona, Deputy Director MCCC Florida, and 5 Associate Directors. There have been a number of changes since the last renewal. As part of a planned succession following the successful 2003 CCSG competitive renewal, Dr. Robert Diasio was recruited as Cancer Center Director in a national search initiated in mid 2005 culminating with his appointment effective September 1, 2006. Dr. Charles Erlichman, previously an MCCC Associate Director, was appointed Deputy Director for Clinical Affairs in late 2004. In his position as Deputy Director for Clinical Affairs, he has primary responsibility for overseeing and implementing integration of the Cancer Center's clinical research activities across all three sites. Also in late 2004, Dr. Robert Smallridge was formally appointed as Deputy Director for MCCC Florida;having previously been the acting Deputy Director. Dr. Rafael Fonseca, co-program leader of the Hematologic Malignancies Program, was appointed as Deputy Director for MCCC Arizona in July 2006 succeeding Dr. Laurence J. Miller who stepped down to focus on his responsibilities as Associate Dean for Research at Mayo Clinic and Director for Research at Mayo Clinic Arizona. Senior Leadership otherwise remains unchanged at the level of the Associate Directors with Dr. Ed Leof continuing as Associate Director for Basic Sciences, Dr. Gloria Petersen as Associate Director for Population Sciences, Dr. Robert Jenkins as Associate Director for Translational Research, Mr. Michael Pfenning as Associate Director for Administration and Dr. Lynn Hartmann as Associate Director for Education and Training. SENIOR/

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications